nach oben

Journal of Nephrology

Erschienen in:

01.06.2017 | Review

Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients

verfasst von: Rosanna Coppo

Erschienen in: Journal of Nephrology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The identification of risk factors conditioning the progression of immunoglobulin (Ig)A nephropathy (IgAN) is needed due to the variability of the outcome of this renal disease, which ranges from remission or indolent course to progressive slow loss of renal function or rapidly evolving chronic renal failure. Based on the supposed individual risk of progression, the therapy is modulated from renin-angiotensin inhibitors to corticosteroids, alone or associated with other powerful but potentially harmful immunosuppressors. Over the last 20 years, several studies have produced great advances in the field of biomarkers for detecting risk factors that play a role in the progression of IgAN. This review will focus on the clinical and histological risk factors which have been detected and validated by the majority of the studies and which may presently be considered of value for prognostication of outcome in patients with IgAN, driving the individual treatment choice.

Magistroni R, D’Agati VD, Appel GB, Kiryluk K (2015) New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 88:974–989CrossRefPubMedPubMedCentral

Coppo R (2008) Pediatric IgA nephropathy: clinical and therapeutic perspectives. Semin Nephrol 28:18–26CrossRefPubMed

Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, Kaito H, Nozu K, Tanaka R, Iijima K, Yoshikawa N (2013) Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 28:71–76CrossRefPubMed

Coppo R, D’Amico G (2005) Factors predicting progression of IgA nephropathies. J Nephrol 18:503–512PubMed

Kiryluk K, Novak J (2014) The genetics and immunobiology of IgA nephropathy. J Clin Invest 124:2325–2332CrossRefPubMedPubMedCentral

Fassbinder W, Brunner FP, Brynger H, Ehrich JH, Geerlings W, Raine AE, Rizzoni G, Selwood NH, Tufveson G, Wing AJ (1991) Combined report on regular dialysis and transplantation in Europe, XX, 1989. Nephrol Dial Transplant 6(Suppl 1):5–35CrossRef

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (2011) The pathophysiology of IgA nephropathy. J Am SocNephrol 22:1795–1803

Coppo R (2016) Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol. PMID: 27324471

Maixnerova D, Reily C, Bian Q, Neprasova M, Novak J, Tesar V (2016) Markers for the progression of IgA nephropathy. J Nephrol 29:535–541CrossRefPubMed

10.

Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Gr, e JP (1997) Predicting renal outcome in IgA nephropathy. J Am SocNephrol 8:199–207

11.

Jafar TH, Schmid CH, Landa M et al (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73–87CrossRefPubMed

12.

Sarafidis PA, Khosla N, Bakris GL (2007) Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49:12–26CrossRefPubMed

13.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO clinical practice guideline for glomerulonephritis. Immunoglobulin Nephrop Kidney Int Suppl 2:139–274

14.

Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V (2013) Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185:949–957CrossRefPubMedPubMedCentral

15.

Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, Itabashi M, Takei T, Uchida K, Nitta K (2014) Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One 21;9(3):e91756.doi:10.1371/journal.pone.0091756 CrossRefPubMedPubMedCentral

16.

Coppo R, Lofaro DD, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E (2016) Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. Pediatr Nephrol [Epub ahead of print]

17.

Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC (2016) The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89:167–175CrossRefPubMed

18.

Kamei K, Harada R, Hamada R, Sakai T, Hamasaki Y, Hataya H, Ito S, Ishikura K, Honda M (2016) Proteinuria during Follow-Up Period and Long-Term Renal Survival of Childhood IgA Nephropathy. PLoS One 11(3):e0150885. doi:10.1371/journal.pone.0150885 CrossRefPubMedPubMedCentral

19.

Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L (2011) Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22:752–761CrossRefPubMedPubMedCentral

20.

Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Tsuchimoto A, Noguchi H, Hirakata H, Tsuruya K, Kitazono T (2013) Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol 8:2082–2090CrossRefPubMedPubMedCentral

21.

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J (2015) STOP-IgAN Investigators: Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 373:2225–2236CrossRefPubMed

22.

Berthoux F, Mariat C, Maillard N (2013) Overweight/obesity revisited as a predictive risk factor in primary IgA nephropathy. Nephrol Dial Transplant. Suppl 4:iv160–iv166. doi:10.1093/ndt/gft286

23.

Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, FerrarioF, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group (2014) :Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 86:828–836CrossRefPubMedPubMedCentral

24.

Knoop T, Vågane AM, Vikse BE, Svarstad E, Magnúsdóttir BT, Leh S, VarbergReisæter A, Bjørneklett R (2015) Addition of eGFR and age improves the prognostic absolute renal risk-model in 1,134 Norwegian patients with IgA nephropathy. Am J Nephrol 41:210–219CrossRefPubMed

25.

Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, Ren H, Pan X, Chen X, Zhang W, Li X, Shi H, Li Y, Gharavi AG, Chen N (2012) Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One 7(6):e38904. doi:10.1371/journal.pone.0038904 CrossRefPubMedPubMedCentral

26.

Zhang L, Li J, Yang S, Huang N, Zhou Q, Yang Q, Yu X (2016) Clinicopathological features and risk factors analysis of IgA nephropathy associated with acute kidney injury. Ren Fail 38:799–805CrossRefPubMed

27.

Iwasaki C, Moriyama T, Tanaka K, Takei T, Nitta K (2016) Effect of hematuria on the outcome of immunoglobulin A nephropathy with proteinuria. J Nephropathol 5:72–78CrossRefPubMedPubMedCentral

28.

Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am SocNephrol 18:3177–3183

29.

Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS (2016) Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis 68:392–401CrossRefPubMed

30.

Bartosik LP, Lajoie G, Sugar L, Cattran DC (2001) Predicting progression in IgA nephropathy. Am J Kidney Dis 38:728–735CrossRefPubMed

31.

Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R; VALIGA study of the ERA-EDTA Immunonephrology Working Group (2015) Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study. J Am SocNephrol 26:2248–2258

32.

Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, Olea T, Martínez-Ara J, Segarra A, Bernis C, García A, Goicoechea M, García de VinuesaS, Rojas-Rivera J, Praga M; Grupo de Estudio de Enfermedades Glomerulares de la ociedad Española de Nefrología (GLOSEN) (2012) Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 23:1753–1760CrossRefPubMedPubMedCentral

33.

Matsushita S, Ishikura K, Okamoto S, Okuda Y, Nagaoka Y, Harada R, Hamada R, Sakai T, Hamasaki Y, Hataya H, Ando T, Ogata K, Honda M (2015) Long-term morbidity of IgA nephropathy in children evaluated with newly proposed remission criteria in Japan. Clin Exp Nephrol 19:1149–1156CrossRefPubMed

34.

Gutiérrez E, Egido J, Rubio-Navarro A, Buendía I, Blanco Colio LM, Toldos O, Manzarbeitia F, de Lorenzo A, Sanchez R, Ortiz A, Praga M, Moreno JA (2012) Oxidative stress, macrophage infiltration and CD163 expression are determinants of long-term renal outcome in macrohematuria-induced acute kidney injury of IgA nephropathy. Nephron Clin Pract 121:c42–53.CrossRefPubMed

35.

Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Tam KY, Xiao J, Lai FM, Tang SC (2009) Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 24:62–72CrossRefPubMed

36.

Coppo R, Fonsato V, Balegno S, Ricotti E, Loiacono E, Camilla R, Peruzzi L, Amore A, Bussolati B, Camussi G (2010) Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int 77:417–427CrossRefPubMed

37.

Cravedi P, Remuzzi G (2013) Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol 76:516–523PubMedPubMedCentral

38.

Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D’Agati V, D’Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76:546–556CrossRefPubMed

39.

Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545CrossRefPubMed

40.

Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2010) The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 77:921–927CrossRefPubMed

41.

Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, Kaito H, Sako M, Iijima K, Yoshikawa N (2012) Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol 27:783–792CrossRefPubMed

42.

Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts IS (2016) Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression. J Nephrol 29:367–375CrossRefPubMed

43.

Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, Zhou ML, Zhang HT, Liu ZH (2015) Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol 28:441–449CrossRefPubMed

44.

Haas M, Verhave JC, Liu ZH, Coppo R, Troyanov S, Katafuchi R (2016) The predictive value of crescents in IgA nephropathy: a large retrospective multicenter study. J Am Soc Nephrol pii: ASN.2016040433. [Epub ahead of print]

45.

Kawamura T, Joh K, Okonogi H, Koike K, Utsunomiya Y, Miyazaki Y, Matsushima M, Yoshimura M, Horikoshi S, Suzuki Y, Furusu A, Yasuda T, Shirai S, Shibata T, Endoh M, Hattori M, Katafuchi R, Hashiguchi A, Kimura K, Matsuo S, Tomino Y (2013) Study group special IgA nephropathy. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol 26:350–357CrossRefPubMed

46.

Espinosa M, Ortega R, Sánchez M, Segarra A, Salcedo MT, González F, Camacho R, Valdivia MA, Cabrera R, López K, Pinedo F, Gutierrez E, Valera A, Leon M, Cobo MA, Rodriguez R, Ballarín J, Arce Y, García B, Muñoz MD, Praga M; Spanish Group for Study of Glomerular Diseases (GLOSEN) (2014) Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 9:897–904CrossRefPubMedPubMedCentral

47.

Roberts IS (2013) Oxford classification of immunoglobulin A nephropathy: an update. Curr Opin Nephrol Hypertens 22:281–286CrossRefPubMed

48.

Coppo R, Davin JC (2015) The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: crescents and timing of renal biopsy. Pediatr Nephrol 30:189–192CrossRefPubMed

49.

Daha MR, van Kooten C (2016) Role of complement in IgA nephropathy. J Nephrol 29:1–4CrossRefPubMed

50.

Pesce F, Diciolla M, Binetti G, Naso D, Ostuni VC, Di Noia T, VåganeAM, Bjørneklett R, Suzuki H, Tomino Y, Di Sciascio E, Schena FP (2016) Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrol Dial Transplant 31:80–86CrossRefPubMed

Titel: Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients
verfasst von: Rosanna Coppo
Publikationsdatum: 01.06.2017
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 3/2017
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-016-0360-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Venous Window Needle Guide for deep vessels and difficult arteriovenous fistula cannulation

Antiplatelet agents in hemodialysis

Erratum to: The exciting “bench to bedside” journey of cell therapies for acute kidney injury and renal transplantation

Ultrasound findings of BK polyomavirus-associated nephropathy in renal transplant patients

Complicated pregnancies in inherited distal renal tubular acidosis: importance of acid-base balance

The modified CKD-EPI equation may be not more accurate than CKD-EPI equation in determining glomerular filtration rate in Chinese patients with chronic kidney disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin